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Background
The RV144 trial showed an estimated 31% vaccine effi-
cacy (VE) against HIV-1 infection. Two immunological
correlates of risk were found in vaccine recipients:
Envelope V1/V2 antibody titers and IgA binding to
Envelope (Haynes et al., 2012).
Methods
We conducted a CD8+ T-cell based sieve analysis of the
V1/V2 region testing for differential escape from vaccine
induced epitopes as predicted using computational meth-
ods. Breakthrough peptides that differed from predicted
epitopes in the vaccine insert and had reduced HLA
binding affinity were considered escapes.
Results
Three of twelve epitopes in V1/V2 of the MN protein
boost showed evidence of escape (start-positions 147,
163, 168 restricted by A*11 and A*02), with more
escapes in vaccine recipients (p=0.018). We hypothe-
sized that if escape was indicative of anamnestic
responses, recipient’s HLA alleles should not modify VE.
While VE was not different in A*11(+/-) subgroups
(p=0.45), it was higher in A*02(+) versus A*02(-) partici-
pants (VE=54% vs. 3%, interaction p-value=0.05). Pre-
vious analysis showed that HIV variants matching the
vaccine insert at site 169 (K169) (in V2, implicated in
antibody binding) were preferentially excluded from
infections in vaccine recipients (VE against K169=48%,
p=0.0036). We found significant VE against K169 in
only the A*02(+) subgroup (74%, p=0.001; p-value for
difference A*02(+/-)=0.01). Reanalyzing the immune
correlates within A*02(+/-) subgroups, we found a direct
correlation between IgA-C1 titers and infection rate in
A*02(-) participants (OR=2.07, p=0.0002), but not in the
A*02(+) participants (OR=1.12, p=0.71; A*02(+/-) inter-
action p-value=0.05).
Conclusion
Our exploratory analysis, driven by a T-cell based sieve
effect in envelope V1/V2, revealed an association
between an HLA class I allele and VE, suggesting that VE
was restricted to A*02(+) participants and that IgA-C1
antibodies inhibited protective effects of other responses
in A*02(-) participants. This highlights the importance of
considering the effects of host genetics on VE in future
HIV vaccine trials.
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